1
|
Fontaine M, Bartolami E, Prono M, Béal D, Blosi M, Costa AL, Ravagli C, Baldi G, Sprio S, Tampieri A, Fenoglio I, Tran L, Fadeel B, Carriere M. Nanomaterial genotoxicity evaluation using the high-throughput p53-binding protein 1 (53BP1) assay. PLoS One 2023; 18:e0288737. [PMID: 37713377 PMCID: PMC10503773 DOI: 10.1371/journal.pone.0288737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 07/04/2023] [Indexed: 09/17/2023] Open
Abstract
Toxicity evaluation of engineered nanomaterials is challenging due to the ever increasing number of materials and because nanomaterials (NMs) frequently interfere with commonly used assays. Hence, there is a need for robust, high-throughput assays with which to assess their hazard potential. The present study aimed at evaluating the applicability of a genotoxicity assay based on the immunostaining and foci counting of the DNA repair protein 53BP1 (p53-binding protein 1), in a high-throughput format, for NM genotoxicity assessment. For benchmarking purposes, we first applied the assay to a set of eight known genotoxic agents, as well as X-ray irradiation (1 Gy). Then, a panel of NMs and nanobiomaterials (NBMs) was evaluated with respect to their impact on cell viability and genotoxicity, and to their potential to induce reactive oxygen species (ROS) production. The genotoxicity recorded using the 53BP1 assay was confirmed using the micronucleus assay, also scored via automated (high-throughput) microscopy. The 53BP1 assay successfully identified genotoxic compounds on the HCT116 human intestinal cell line. None of the tested NMs showed any genotoxicity using the 53BP1 assay, except the positive control consisting in (CoO)(NiO) NMs, while only TiO2 NMs showed positive outcome in the micronucleus assay. Only Fe3O4 NMs caused significant elevation of ROS, not correlated to DNA damage. Therefore, owing to its adequate predictivity of the genotoxicity of most of the tested benchmark substance and its ease of implementation in a high throughput format, the 53BP1 assay could be proposed as a complementary high-throughput screening genotoxicity assay, in the context of the development of New Approach Methodologies.
Collapse
Affiliation(s)
- Maelle Fontaine
- CEA, CNRS, IRIG, SyMMES-CIBEST, Univ. Grenoble Alpes, Grenoble, France
| | - Eline Bartolami
- CEA, CNRS, IRIG, SyMMES-CIBEST, Univ. Grenoble Alpes, Grenoble, France
| | - Marion Prono
- CEA, CNRS, IRIG, SyMMES-CIBEST, Univ. Grenoble Alpes, Grenoble, France
| | - David Béal
- CEA, CNRS, IRIG, SyMMES-CIBEST, Univ. Grenoble Alpes, Grenoble, France
| | - Magda Blosi
- National Research Council, Institute of Science, Technology and Sustainability for Ceramic Materials ISSMC-CNR (Former ISTEC-CNR), Faenza, Italy
| | - Anna L. Costa
- National Research Council, Institute of Science, Technology and Sustainability for Ceramic Materials ISSMC-CNR (Former ISTEC-CNR), Faenza, Italy
| | - Costanza Ravagli
- Ce.Ri.Col, Colorobbia Consulting S.R.L, Sovigliana-Vinci, Firenze, Italy
| | - Giovanni Baldi
- Ce.Ri.Col, Colorobbia Consulting S.R.L, Sovigliana-Vinci, Firenze, Italy
| | - Simone Sprio
- National Research Council, Institute of Science, Technology and Sustainability for Ceramic Materials ISSMC-CNR (Former ISTEC-CNR), Faenza, Italy
| | - Anna Tampieri
- National Research Council, Institute of Science, Technology and Sustainability for Ceramic Materials ISSMC-CNR (Former ISTEC-CNR), Faenza, Italy
| | - Ivana Fenoglio
- Department of Chemistry, University of Turin, Turin, Italy
| | - Lang Tran
- Institute of Occupational Medicine, Edinburgh, Midlothian, United Kingdom
| | - Bengt Fadeel
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Marie Carriere
- CEA, CNRS, IRIG, SyMMES-CIBEST, Univ. Grenoble Alpes, Grenoble, France
| |
Collapse
|
2
|
Tomitaka A, Vashist A, Kolishetti N, Nair M. Machine learning assisted-nanomedicine using magnetic nanoparticles for central nervous system diseases. NANOSCALE ADVANCES 2023; 5:4354-4367. [PMID: 37638161 PMCID: PMC10448356 DOI: 10.1039/d3na00180f] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Accepted: 07/24/2023] [Indexed: 08/29/2023]
Abstract
Magnetic nanoparticles possess unique properties distinct from other types of nanoparticles developed for biomedical applications. Their unique magnetic properties and multifunctionalities are especially beneficial for central nervous system (CNS) disease therapy and diagnostics, as well as targeted and personalized applications using image-guided therapy and theranostics. This review discusses the recent development of magnetic nanoparticles for CNS applications, including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and drug addiction. Machine learning (ML) methods are increasingly applied towards the processing, optimization and development of nanomaterials. By using data-driven approach, ML has the potential to bridge the gap between basic research and clinical research. We review ML approaches used within the various stages of nanomedicine development, from nanoparticle synthesis and characterization to performance prediction and disease diagnosis.
Collapse
Affiliation(s)
- Asahi Tomitaka
- Department of Computer and Information Sciences, College of Natural and Applied Science, University of Houston-Victoria Texas 77901 USA
| | - Arti Vashist
- Department of Immunology and Nano-Medicine, Herbert Wertheim College of Medicine, Florida International University Miami Florida 33199 USA
- Institute of NeuroImmune Pharmacology, Centre for Personalized Nanomedicine, Herbert Wertheim College of Medicine, Florida International University Miami Florida 33199 USA
| | - Nagesh Kolishetti
- Department of Immunology and Nano-Medicine, Herbert Wertheim College of Medicine, Florida International University Miami Florida 33199 USA
- Institute of NeuroImmune Pharmacology, Centre for Personalized Nanomedicine, Herbert Wertheim College of Medicine, Florida International University Miami Florida 33199 USA
| | - Madhavan Nair
- Department of Immunology and Nano-Medicine, Herbert Wertheim College of Medicine, Florida International University Miami Florida 33199 USA
- Institute of NeuroImmune Pharmacology, Centre for Personalized Nanomedicine, Herbert Wertheim College of Medicine, Florida International University Miami Florida 33199 USA
| |
Collapse
|
3
|
Lenders V, Koutsoumpou X, Phan P, Soenen SJ, Allegaert K, de Vleeschouwer S, Toelen J, Zhao Z, Manshian BB. Modulation of engineered nanomaterial interactions with organ barriers for enhanced drug transport. Chem Soc Rev 2023; 52:4672-4724. [PMID: 37338993 DOI: 10.1039/d1cs00574j] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/22/2023]
Abstract
The biomedical use of nanoparticles (NPs) has been the focus of intense research for over a decade. As most NPs are explored as carriers to alter the biodistribution, pharmacokinetics and bioavailability of associated drugs, the delivery of these NPs to the tissues of interest remains an important topic. To date, the majority of NP delivery studies have used tumor models as their tool of interest, and the limitations concerning tumor targeting of systemically administered NPs have been well studied. In recent years, the focus has also shifted to other organs, each presenting their own unique delivery challenges to overcome. In this review, we discuss the recent advances in leveraging NPs to overcome four major biological barriers including the lung mucus, the gastrointestinal mucus, the placental barrier, and the blood-brain barrier. We define the specific properties of these biological barriers, discuss the challenges related to NP transport across them, and provide an overview of recent advances in the field. We discuss the strengths and shortcomings of different strategies to facilitate NP transport across the barriers and highlight some key findings that can stimulate further advances in this field.
Collapse
Affiliation(s)
- Vincent Lenders
- Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000 Leuven, Belgium.
| | - Xanthippi Koutsoumpou
- Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000 Leuven, Belgium.
| | - Philana Phan
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
| | - Stefaan J Soenen
- Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000 Leuven, Belgium.
- NanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000 Leuven, Belgium
| | - Karel Allegaert
- Department of Hospital Pharmacy, Erasmus MC University Medical Center, CN Rotterdam, 3015, The Netherlands
- Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, B3000 Leuven, Belgium
- Leuven Child and Youth Institute, KU Leuven, 3000 Leuven, Belgium
- Woman and Child, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium
| | - Steven de Vleeschouwer
- Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
- Laboratory of Experimental Neurosurgery and Neuroanatomy, Department of Neurosciences, KU Leuven, Leuven, Belgium
- Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium
| | - Jaan Toelen
- Leuven Child and Youth Institute, KU Leuven, 3000 Leuven, Belgium
- Woman and Child, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium
- Department of Pediatrics, University Hospitals Leuven, 3000 Leuven, Belgium
| | - Zongmin Zhao
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
| | - Bella B Manshian
- Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Herestraat 49, B3000 Leuven, Belgium.
| |
Collapse
|
4
|
Lomphithak T, Helvacioglu S, Armenia I, Keshavan S, Ovejero JG, Baldi G, Ravagli C, Grazú V, Fadeel B. High-Dose Exposure to Polymer-Coated Iron Oxide Nanoparticles Elicits Autophagy-Dependent Ferroptosis in Susceptible Cancer Cells. NANOMATERIALS (BASEL, SWITZERLAND) 2023; 13:nano13111719. [PMID: 37299622 DOI: 10.3390/nano13111719] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 05/10/2023] [Accepted: 05/18/2023] [Indexed: 06/12/2023]
Abstract
Ferroptosis, a form of iron-dependent, lipid peroxidation-driven cell death, has been extensively investigated in recent years, and several studies have suggested that the ferroptosis-inducing properties of iron-containing nanomaterials could be harnessed for cancer treatment. Here we evaluated the potential cytotoxicity of iron oxide nanoparticles, with and without cobalt functionalization (Fe2O3 and Fe2O3@Co-PEG), using an established, ferroptosis-sensitive fibrosarcoma cell line (HT1080) and a normal fibroblast cell line (BJ). In addition, we evaluated poly (ethylene glycol) (PEG)-poly(lactic-co-glycolic acid) (PLGA)-coated iron oxide nanoparticles (Fe3O4-PEG-PLGA). Our results showed that all the nanoparticles tested were essentially non-cytotoxic at concentrations up to 100 μg/mL. However, when the cells were exposed to higher concentrations (200-400 μg/mL), cell death with features of ferroptosis was observed, and this was more pronounced for the Co-functionalized nanoparticles. Furthermore, evidence was provided that the cell death triggered by the nanoparticles was autophagy-dependent. Taken together, the exposure to high concentrations of polymer-coated iron oxide nanoparticles triggers ferroptosis in susceptible human cancer cells.
Collapse
Affiliation(s)
- Thanpisit Lomphithak
- Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden
- Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Selin Helvacioglu
- Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden
- Department of Molecular Biology and Genetics, Izmir Institute of Technology, Izmir 35433, Turkey
| | - Ilaria Armenia
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50001 Zaragoza, Spain
| | - Sandeep Keshavan
- Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden
| | - Jesús G Ovejero
- Instituto de Ciencia de Materiales de Madrid (ICMM-CSIC), 28049 Madrid, Spain
- Department of Dosimetry and Radioprotection, General University Hospital Gregorio Marañón, 28049 Madrid, Spain
| | - Giovanni Baldi
- Colorobbia Consulting S.R.L., Sovigliana, 50053 Vinci, Italy
| | | | - Valeria Grazú
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50001 Zaragoza, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 50018 Zaragoza, Spain
| | - Bengt Fadeel
- Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden
| |
Collapse
|
5
|
Ou A, Wang Y, Zhang J, Huang Y. Living Cells and Cell-Derived Vesicles: A Trojan Horse Technique for Brain Delivery. Pharmaceutics 2023; 15:pharmaceutics15041257. [PMID: 37111742 PMCID: PMC10145830 DOI: 10.3390/pharmaceutics15041257] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 03/30/2023] [Accepted: 04/06/2023] [Indexed: 04/29/2023] Open
Abstract
Brain diseases remain a significant global healthcare burden. Conventional pharmacological therapy for brain diseases encounters huge challenges because of the blood-brain barrier (BBB) limiting the delivery of therapeutics into the brain parenchyma. To address this issue, researchers have explored various types of drug delivery systems. Cells and cell derivatives have attracted increasing interest as "Trojan horse" delivery systems for brain diseases, owing to their superior biocompatibility, low immunogenicity, and BBB penetration properties. This review provided an overview of recent advancements in cell- and cell-derivative-based delivery systems for the diagnosis and treatment of brain diseases. Additionally, it discussed the challenges and potential solutions for clinical translation.
Collapse
Affiliation(s)
- Ante Ou
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - Yuewei Wang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - Jiaxin Zhang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Yongzhuo Huang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- University of Chinese Academy of Sciences, Beijing 100049, China
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528437, China
- NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, Shanghai 201203, China
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
| |
Collapse
|
6
|
Marassi V, Zanoni I, Ortelli S, Giordani S, Reschiglian P, Roda B, Zattoni A, Ravagli C, Cappiello L, Baldi G, Costa AL, Blosi M. Native Study of the Behaviour of Magnetite Nanoparticles for Hyperthermia Treatment during the Initial Moments of Intravenous Administration. Pharmaceutics 2022; 14:2810. [PMID: 36559302 PMCID: PMC9782478 DOI: 10.3390/pharmaceutics14122810] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 12/06/2022] [Accepted: 12/13/2022] [Indexed: 12/23/2022] Open
Abstract
Magnetic nanoparticles (MNPs) present outstanding properties making them suitable as therapeutic agents for hyperthermia treatments. Since the main safety concerns of MNPs are represented by their inherent instability in a biological medium, strategies to both achieve long-term stability and monitor hazardous MNP degradation are needed. We combined a dynamic approach relying on flow field flow fractionation (FFF)-multidetection with conventional techniques to explore frame-by-frame changes of MNPs injected in simulated biological medium, hypothesize the interaction mechanism they are subject to when surrounded by a saline, protein-rich environment, and understand their behaviour at the most critical point of intravenous administration. In the first moments of MNPs administration in the patient, MNPs change their surrounding from a favorable to an unfavorable medium, i.e., a complex biological fluid such as blood; the particles evolve from a synthetic identity to a biological identity, a transition that needs to be carefully monitored. The dynamic approach presented herein represents an optimal alternative to conventional batch techniques that can monitor only size, shape, surface charge, and aggregation phenomena as an averaged information, given that they cannot resolve different populations present in the sample and cannot give accurate information about the evolution or temporary instability of MNPs. The designed FFF method equipped with a multidetection system enabled the separation of the particle populations providing selective information on their morphological evolution and on nanoparticle-proteins interaction in the very first steps of infusion. Results showed that in a dynamic biological setting and following interaction with serum albumin, PP-MNPs retain their colloidal properties, supporting their safety profile for intravenous administration.
Collapse
Affiliation(s)
- Valentina Marassi
- Department of Chemistry G. Ciamician, University of Bologna, Via Selmi 2, 40126 Bologna, Italy
- Stem Sel srl, University of Bologna, 40129 Bologna, Italy
| | - Ilaria Zanoni
- CNR-ISSMC, Institute of Science, Technology and Sustainability for Ceramics (Former ISTEC), Via Granarolo 64, 48018 Faenza, Italy
| | - Simona Ortelli
- CNR-ISSMC, Institute of Science, Technology and Sustainability for Ceramics (Former ISTEC), Via Granarolo 64, 48018 Faenza, Italy
| | - Stefano Giordani
- Department of Chemistry G. Ciamician, University of Bologna, Via Selmi 2, 40126 Bologna, Italy
| | - Pierluigi Reschiglian
- Department of Chemistry G. Ciamician, University of Bologna, Via Selmi 2, 40126 Bologna, Italy
- Stem Sel srl, University of Bologna, 40129 Bologna, Italy
| | - Barbara Roda
- Department of Chemistry G. Ciamician, University of Bologna, Via Selmi 2, 40126 Bologna, Italy
- Stem Sel srl, University of Bologna, 40129 Bologna, Italy
| | - Andrea Zattoni
- Department of Chemistry G. Ciamician, University of Bologna, Via Selmi 2, 40126 Bologna, Italy
- Stem Sel srl, University of Bologna, 40129 Bologna, Italy
| | - Costanza Ravagli
- Ce.Ri.Col, Colorobbia Consulting S.R.L., 50059 Sovigliana Vinci, Italy
| | - Laura Cappiello
- Ce.Ri.Col, Colorobbia Consulting S.R.L., 50059 Sovigliana Vinci, Italy
| | - Giovanni Baldi
- Ce.Ri.Col, Colorobbia Consulting S.R.L., 50059 Sovigliana Vinci, Italy
| | - Anna L. Costa
- CNR-ISSMC, Institute of Science, Technology and Sustainability for Ceramics (Former ISTEC), Via Granarolo 64, 48018 Faenza, Italy
| | - Magda Blosi
- CNR-ISSMC, Institute of Science, Technology and Sustainability for Ceramics (Former ISTEC), Via Granarolo 64, 48018 Faenza, Italy
| |
Collapse
|
7
|
Martin S, de Haan L, Miro Estruch I, Eder KM, Marzi A, Schnekenburger J, Blosi M, Costa A, Antonello G, Bergamaschi E, Riganti C, Beal D, Carrière M, Taché O, Hutchison G, Malone E, Young L, Campagnolo L, La Civita F, Pietroiusti A, Devineau S, Baeza A, Boland S, Zong C, Ichihara G, Fadeel B, Bouwmeester H. Pre-validation of a reporter gene assay for oxidative stress for the rapid screening of nanobiomaterials. FRONTIERS IN TOXICOLOGY 2022; 4:974429. [PMID: 36171865 PMCID: PMC9511406 DOI: 10.3389/ftox.2022.974429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Accepted: 08/09/2022] [Indexed: 12/04/2022] Open
Abstract
Engineered nanomaterials have been found to induce oxidative stress. Cellular oxidative stress, in turn, can result in the induction of antioxidant and detoxification enzymes which are controlled by the nuclear erythroid 2-related factor 2 (NRF2) transcription factor. Here, we present the results of a pre-validation study which was conducted within the frame of BIORIMA (“biomaterial risk management”) an EU-funded research and innovation project. For this we used an NRF2 specific chemically activated luciferase expression reporter gene assay derived from the human U2OS osteosarcoma cell line to screen for the induction of the NRF2 mediated gene expression following exposure to biomedically relevant nanobiomaterials. Specifically, we investigated Fe3O4-PEG-PLGA nanomaterials while Ag and TiO2 “benchmark” nanomaterials from the Joint Research Center were used as reference materials. The viability of the cells was determined by using the Alamar blue assay. We performed an interlaboratory study involving seven different laboratories to assess the applicability of the NRF2 reporter gene assay for the screening of nanobiomaterials. The latter work was preceded by online tutorials to ensure that the procedures were harmonized across the different participating laboratories. Fe3O4-PEG-PLGA nanomaterials were found to induce very limited NRF2 mediated gene expression, whereas exposure to Ag nanomaterials induced NRF2 mediated gene expression. TiO2 nanomaterials did not induce NRF2 mediated gene expression. The variability in the results obtained by the participating laboratories was small with mean intra-laboratory standard deviation of 0.16 and mean inter laboratory standard deviation of 0.28 across all NRF2 reporter gene assay results. We conclude that the NRF2 reporter gene assay is a suitable assay for the screening of nanobiomaterial-induced oxidative stress responses.
Collapse
Affiliation(s)
- Sebastin Martin
- Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Laura de Haan
- Division of Toxicology, Wageningen University and Research, Wageningen, Netherlands
| | - Ignacio Miro Estruch
- Division of Toxicology, Wageningen University and Research, Wageningen, Netherlands
| | - Kai Moritz Eder
- Biomedical Technology Center, Westfälische Wilhelms-University, Münster, Germany
| | - Anne Marzi
- Biomedical Technology Center, Westfälische Wilhelms-University, Münster, Germany
| | | | - Magda Blosi
- Institute of Science and Technology for Ceramics (ISTEC), CNR, Faenza, Italy
| | - Anna Costa
- Institute of Science and Technology for Ceramics (ISTEC), CNR, Faenza, Italy
| | | | - Enrico Bergamaschi
- Department of Public Health and Pediatrics, University of Torino, Torino, Italy
| | - Chiara Riganti
- Department of Chemistry, University of Torino, Torino, Italy
| | - David Beal
- Université Grenoble-Alpes, CEA, CNRS, IRIG, SyMMES, Grenoble, France
| | - Marie Carrière
- Université Grenoble-Alpes, CEA, CNRS, IRIG, SyMMES, Grenoble, France
| | - Olivier Taché
- Université Paris-Saclay, CEA, CNRS, NIMBE, Gif-sur-Yvette, France
| | - Gary Hutchison
- School of Applied Sciences, Edinburgh Napier University, Edinburgh, United Kingdom
| | - Eva Malone
- School of Applied Sciences, Edinburgh Napier University, Edinburgh, United Kingdom
| | - Lesley Young
- School of Applied Sciences, Edinburgh Napier University, Edinburgh, United Kingdom
| | - Luisa Campagnolo
- Université Paris Cité, CNRS, Unité de Biologie Fonctionnelle et Adaptative, F-75013 Paris, France
| | - Fabio La Civita
- Université Paris Cité, CNRS, Unité de Biologie Fonctionnelle et Adaptative, F-75013 Paris, France
| | - Antonio Pietroiusti
- Université Paris Cité, CNRS, Unité de Biologie Fonctionnelle et Adaptative, F-75013 Paris, France
| | - Stéphanie Devineau
- Université Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, Paris, France
| | - Armelle Baeza
- Université Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, Paris, France
| | - Sonja Boland
- Université Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, Paris, France
| | - Cai Zong
- Department of Occupational and Environmental Health, Tokyo University of Science, Tokyo, Japan
| | - Gaku Ichihara
- Department of Occupational and Environmental Health, Tokyo University of Science, Tokyo, Japan
| | - Bengt Fadeel
- Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Hans Bouwmeester
- Division of Toxicology, Wageningen University and Research, Wageningen, Netherlands
- *Correspondence: Hans Bouwmeester,
| |
Collapse
|
8
|
|
9
|
Jahromi LP, Shahbazi M, Maleki A, Azadi A, Santos HA. Chemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2021; 8:2002499. [PMID: 33898169 PMCID: PMC8061401 DOI: 10.1002/advs.202002499] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 11/26/2020] [Indexed: 05/16/2023]
Abstract
Over the past decades, considerable attention has been dedicated to the exploitation of diverse immune cells as therapeutic and/or diagnostic cell-based microrobots for hard-to-treat disorders. To date, a plethora of therapeutics based on alive immune cells, surface-engineered immune cells, immunocytes' cell membranes, leukocyte-derived extracellular vesicles or exosomes, and artificial immune cells have been investigated and a few have been introduced into the market. These systems take advantage of the unique characteristics and functions of immune cells, including their presence in circulating blood and various tissues, complex crosstalk properties, high affinity to different self and foreign markers, unique potential of their on-demand navigation and activity, production of a variety of chemokines/cytokines, as well as being cytotoxic in particular conditions. Here, the latest progress in the development of engineered therapeutics and diagnostics inspired by immune cells to ameliorate cancer, inflammatory conditions, autoimmune diseases, neurodegenerative disorders, cardiovascular complications, and infectious diseases is reviewed, and finally, the perspective for their clinical application is delineated.
Collapse
Affiliation(s)
- Leila Pourtalebi Jahromi
- Drug Research ProgramDivision of Pharmaceutical Chemistry and TechnologyFaculty of PharmacyUniversity of HelsinkiHelsinkiFI‐00014Finland
- Pharmaceutical Sciences Research CenterShiraz University of Medical SciencesShiraz71468‐64685Iran
- Present address:
Helmholtz Institute for Pharmaceutical Research SaarlandHelmholtz Centre for Infection ResearchBiogenic Nanotherapeutics GroupCampus E8.1Saarbrücken66123Germany
| | - Mohammad‐Ali Shahbazi
- Drug Research ProgramDivision of Pharmaceutical Chemistry and TechnologyFaculty of PharmacyUniversity of HelsinkiHelsinkiFI‐00014Finland
- Zanjan Pharmaceutical Nanotechnology Research Center (ZPNRC)Zanjan University of Medical SciencesZanjan45139‐56184Iran
| | - Aziz Maleki
- Zanjan Pharmaceutical Nanotechnology Research Center (ZPNRC)Zanjan University of Medical SciencesZanjan45139‐56184Iran
| | - Amir Azadi
- Pharmaceutical Sciences Research CenterShiraz University of Medical SciencesShiraz71468‐64685Iran
- Department of PharmaceuticsSchool of PharmacyShiraz University of Medical SciencesShiraz71468‐64685Iran
| | - Hélder A. Santos
- Drug Research ProgramDivision of Pharmaceutical Chemistry and TechnologyFaculty of PharmacyUniversity of HelsinkiHelsinkiFI‐00014Finland
- Helsinki Institute of Life Science (HiLIFE)University of HelsinkiHelsinkiFI‐00014Finland
| |
Collapse
|
10
|
T Cell Delivery of Nanoparticles-Bound Anti-CD20 Monoclonal Antibody: Successful B Cell Depletion in the Spinal Cord during Experimental Autoimmune Encephalomyelitis. J Neuroimmune Pharmacol 2020; 16:376-389. [PMID: 32514635 DOI: 10.1007/s11481-020-09931-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 06/01/2020] [Indexed: 10/24/2022]
Abstract
We developed a nanotechnology based-cell mediated drug delivery system by loading myelin antigen-specific T cells with nanoparticles bound to anti-CD20 monoclonal antibody. Anti-CD20 antibody is a current treatment (ocrelizumab) for multiple sclerosis (MS), a chronic, inflammatory and autoimmune disease of the central nervous system (CNS). CD20-depletion has been associated with efficacy in active relapsing and progressive MS, but may not efficiently target inflammatory cells compartmentalized in the CNS. In our work, the intravenous transfer of T cells containing nanoparticle-anti-CD20 complex in mice causes B cell depletion in the spleen and in the brain, whereas the injection of anti-CD20 alone depletes B cells only in the spleen. Testing this system in Experimental Autoimmune Encephalomyelitis (EAE), animal model of MS, we found that spinal cord B cell depletion ameliorates the disease course and pathology. Graphical Abstract.
Collapse
|